Novo Nordisk's blockbuster weight-loss drug semaglutide's core patent will expire in China in 2026, facing fierce competition

Summary

Novo Nordisk’s core patent for the weight-loss drug semaglutide will expire in China in 2026, leading to expected intense competition from local pharmaceutical companies developing generic versions.QQ News+ 2QQ News

Impact Analysis

So basically, Novo Nordisk is bracing for a storm in China as its semaglutide patent nears expiration in 2026. This isn’t just about losing exclusivity; it’s about a flood of cheaper generics that could erode their market share and pricing power significantly. The interesting part isn’t just the patent expiration, but how Novo Nordisk is scrambling to mitigate the impact. They’re fast-tracking the oral version of semaglutide, which could be a game-changer if it gains FDA approval by year-end, becoming the first oral GLP-1 weight-loss drug globally QQ News. Meanwhile, local Chinese firms are gearing up for a price war, which could reshape the market dynamics entirely QQ News+ 2. The market might be underestimating the speed and scale of this competitive shift. Watching how Novo Nordisk’s strategic pivots play out will be crucial, especially their cost-cutting and restructuring efforts to stay competitive 时代财经+ 2.